VC-backed Dicerna Pharmaceuticals sets pricing terms for IPO

According to Fortune, Dicerna Pharmaceuticals has priced its IPO of 5 million shares at between $11 and $13 per share. The stock will trade on the NASDAQ under the ticker symbol “DRNA.” Jefferies, Leerink Swann and Stifel are acting as lead underwriters. Based in Watertown, Mass., Dicerna Pharmaceuticals is a developer of RNA interference-based therapeutics. Its backers include Domain Associates, Skyline Ventures, Deerfield Management, RA Capital, Abingworth Management, Brookside Capital, S.R. One Ltd. and Oxford Bioscience Partners.

Leave a Reply

PEHUB Community

Join the 12505 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget